ViGeneron signs gene therapy collaboration agreement with Regeneron Pharmaceuticals
This agreement is on developing and commercialising a gene therapy product based on ViGeneron’s engineered recombinant adeno-associated virus vectors (vgAAVs) to treat an inherited retinal disease (IRD). As